Antiplatelet drugs may cause retinal bleeding in age-related macular degenerative patients — 5 points

In a study published in the journal Ophthalmology, researchers found anticoagulant and antiplatelet drugs may increase the risk for retinal or subretinal bleeding by 50 percent in people who have a combination of neovascular age-related macular degeneration and hypertension, according to a Medscape report.

Advertisement

The study authors examined 43 United States centers who treated patients 50 years old or older for untreated active choroidal neovascularization.

Here are five points on the findings:

1. Among 1,165 participants with gradable fundus photographs, 52.2 percent used one or more antiplatelet or anticoagulant drugs at baseline, including 44.1 percent with antiplatelet drugs only, 6.6 percent with anticoagulant drugs only and 1.5 percent with both types of medication.

2. The most frequently-used of these drugs were aspiring at 69.4 percent, warfarin at 14.7 percent and clopidregel at 11.4 percent.

3. At baseline, 62.1 percent of the participants with gradable photographs had retinal or subretinal hemorrhage. Of these, 84.4 percent were one disc area or less, 8.1 percent were one to two disc areas and 7.5 percent were more than two disc areas.

4. The participants with hemorrhages at baseline were older on average and had slightly lower mean diastolic blood pressure, but they had a similar history of cardiovascular disease, hypertension, diabetes, osteoarthritis and rheumatoid arthritis.

5. Of the 608 participants taking antiplatelet or anticoagulant drugs, 64.5 percent had retinal or subretinal hemorrhage. In comparison, 59.6 percent of 507 participants who did not take antiplatelet or anticoagulant drugs had such hemorrhages.

More articles on healthcare:
7 things for ASC leaders to know for Thursday — Feb. 18, 2016
Ambulatory service market to reach $3T — 5 things to know
Joint Commission on Allied Health Personnel in Ophthalmology names Dr. Eydie Miller-Ellis president: 3 notes

Advertisement

Next Up in ASC News

Advertisement

Comments are closed.